ICARE Newsletter Summer 2016

Surveillance Among Individuals with Li-Fraumeni Syndrome (LFS): An 11 Year Follow-Up Study

Results from the original screening protocol for LFS1 were recently updated following collection of 11 years of follow-up data.2 Through this study, 89 patients with LFS were given the option of a clinical surveillance protocol consisting of a physical examination as well as frequent biochemical and imaging studies. Forty asymptomatic tumors were detected in 32% of the TP53 mutation carriers who chose clinical surveillance. Overall survival was much higher in the surveillance group (almost 90%) compared to the non-surveillance group (~60%). These data imply benefits from ongoing comprehensive cancer surveillance with early detection of tumors with suggestions that overall survival may be improved. 

1Villani et al. Lancet Oncol. 2011 June. PMID: 21601526.
2Villani et al. Lancet Oncol. 2016 Aug 5. PMID: 27501770.

Permanent link to this article: https://inheritedcancer.net/4nls2016/